Xpgc46t Single Nucleotide Polymorphism With Advanced Colorectal Cancer Oxaliplatin Chemotherapy Sensitivity

OBJECTIVE:DNA repair capacity correlated with sensitivity of cancer cells towards platin-based chemotherapy.To investigate the association between genetic polymorphisms of XPGC46T and response to oxaliplatin-based chemotherapy of colorectal cancer in stageⅣ.METHODS:Blood samples of 73 patients with colorectal cancer in stageⅣwere obtained from each patient before chemotherapy for DNA isolation.XPG genotypes were detected by TaqMan-MGB probe methods.To evaluate clinical response of 73 patients receiving oxaliplatin chemotherapy after 2 cycles of chemotherapy.Also progression-free survival(PFS) of all patients were evaluated. RESULTS:Patients with C/C genotype(73%) showed enhanced respond to chemotherapy compared to those with C/T+T/T(44.4%),P=0.014.The median PFS of patients with C/C genotype was was 11 months;C/T and T/T was 6 months.There was a significant difference between them(p<0.01).CONCLUSION:The results suggest that the XPGC46T genetic polymorphisms may be associated with clinical responses to oxaliplatin-based chemotherapy and survival time in advanced colorectal cancer.